Literature DB >> 25575715

Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.

Francesco Cantiello1, Giorgio Ivan Russo2, Matteo Ferro3, Antonio Cicione4, Sebastiano Cimino2, Vincenzo Favilla2, Sisto Perdonà5, Danilo Bottero3, Daniela Terracciano6, Ottavio De Cobelli3, Giuseppe Morgia2, Rocco Damiano4.   

Abstract

OBJECTIVE: To compare the prognostic accuracy of Prostate Health Index (PHI) and Prostate Cancer Antigen 3 in predicting pathologic features in a cohort of patients who underwent radical prostatectomy (RP) for prostate cancer (PCa). METHODS AND MATERIALS: We evaluated 156 patients with biopsy-proven, clinically localized PCa who underwent RP between January 2013 and December 2013 at 2 tertiary care institutions. Blood and urinary specimens were collected before initial prostate biopsy for [-2] pro-prostate-specific antigen (PSA), its derivates, and PCA3 measurements. Univariate and multivariate logistic regression analyses were carried out to determine the variables that were potentially predictive of tumor volume > 0.5 ml, pathologic Gleason sum ≥ 7, pathologically confirmed significant PCa, extracapsular extension, and seminal vesicles invasions.
RESULTS: On multivariate analyses and after bootstrapping with 1,000 resampled data, the inclusion of PHI significantly increased the accuracy of a baseline multivariate model, which included patient age, total PSA, free PSA, rate of positive cores, clinical stage, prostate volume, body mass index, and biopsy Gleason score (GS), in predicting the study outcomes. Particularly, to predict tumor volume > 0.5, the addition of PHI to the baseline model significantly increased predictive accuracy by 7.9% (area under the receiver operating characteristics curve [AUC] = 89.3 vs. 97.2, P>0.05), whereas PCA3 did not lead to a significant increase. Although both PHI and PCA3 significantly improved predictive accuracy to predict extracapsular extension compared with the baseline model, achieving independent predictor status (all P's < 0.01), only PHI led to a significant improvement in the prediction of seminal vesicles invasions (AUC = 92.2, P < 0.05 with a gain of 3.6%). In the subset of patients with GS ≤ 6, PHI significantly improved predictive accuracy by 7.6% compared with the baseline model (AUC = 89.7 vs. 97.3) to predict pathologically confirmed significant PCa and by 5.9% compared with the baseline model (AUC = 83.1 vs. 89.0) to predict pathologic GS ≥ 7. For these outcomes, PCA3 did not add incremental predictive value.
CONCLUSIONS: In a cohort of patients who underwent RP, PHI is significantly better than PCA3 in the ability to predict the presence of both more aggressive and extended PCa.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Active surveillance; PCA3; PHI; Prognostic accuracy; Prostate cancer; Radical prostatectomy

Mesh:

Substances:

Year:  2015        PMID: 25575715     DOI: 10.1016/j.urolonc.2014.12.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  19 in total

1.  Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

Authors:  G I Russo; T Castelli; V Favilla; G Reale; D Urzì; S Privitera; E Fragalà; S Cimino; G Morgia
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-02       Impact factor: 5.554

Review 2.  The role of prostate cancer biomarkers in undiagnosed men.

Authors:  Hasan Dani; Stacy Loeb
Journal:  Curr Opin Urol       Date:  2017-05       Impact factor: 2.309

3.  PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance.

Authors:  Francesco Cantiello; Giorgio Ivan Russo; Antonio Cicione; Matteo Ferro; Sebastiano Cimino; Vincenzo Favilla; Sisto Perdonà; Ottavio De Cobelli; Carlo Magno; Giuseppe Morgia; Rocco Damiano
Journal:  World J Urol       Date:  2015-07-21       Impact factor: 4.226

Review 4.  The Prostate Health Index: Its Utility in Prostate Cancer Detection.

Authors:  Abbey Lepor; William J Catalona; Stacy Loeb
Journal:  Urol Clin North Am       Date:  2016-02       Impact factor: 2.241

Review 5.  Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.

Authors:  Stacy Loeb; Hans Lilja; Andrew Vickers
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

6.  Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy.

Authors:  Sascha Kaufmann; Giorgio I Russo; Fabian Bamberg; Lorenz Löwe; Giuseppe Morgia; Konstantin Nikolaou; Arnulf Stenzl; Stephan Kruck; Jens Bedke
Journal:  World J Urol       Date:  2018-01-27       Impact factor: 4.226

Review 7.  Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.

Authors:  Stacy Loeb; Hasan Dani
Journal:  Urol Clin North Am       Date:  2017-11       Impact factor: 2.241

8.  Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging.

Authors:  Ottavio de Cobelli; Daniela Terracciano; Elena Tagliabue; Sara Raimondi; Danilo Bottero; Antonio Cioffi; Barbara Jereczek-Fossa; Giuseppe Petralia; Giovanni Cordima; Gilberto Laurino Almeida; Giuseppe Lucarelli; Carlo Buonerba; Deliu Victor Matei; Giuseppe Renne; Giuseppe Di Lorenzo; Matteo Ferro
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 9.  Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS).

Authors:  Matteo Ferro; Paola Ungaro; Amelia Cimmino; Giuseppe Lucarelli; Gian Maria Busetto; Francesco Cantiello; Rocco Damiano; Daniela Terracciano
Journal:  Int J Mol Sci       Date:  2017-05-27       Impact factor: 5.923

Review 10.  Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice.

Authors:  Belén Pastor-Navarro; José Rubio-Briones; Ángel Borque-Fernando; Luis M Esteban; Jose Luis Dominguez-Escrig; José Antonio López-Guerrero
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.